{"id":527,"date":"2026-06-22T00:55:00","date_gmt":"2026-06-22T04:55:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=527"},"modified":"2026-05-16T22:17:07","modified_gmt":"2026-05-17T02:17:07","slug":"ai-doesnt-read-drug-labels-like-humans-do-and-pharma-is-paying-the-price","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/ai-doesnt-read-drug-labels-like-humans-do-and-pharma-is-paying-the-price\/","title":{"rendered":"AI Doesn’t Read Drug Labels Like Humans Do \u2014 And Pharma Is Paying the Price"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

When a patient types “can I take Ozempic with metformin” into ChatGPT, they are not reading an FDA-approved label. They are reading a probabilistic reconstruction of one \u2014 assembled from training data that may include outdated prescribing information, Reddit posts, expired package inserts, and academic abstracts that predate the current approved indication.<\/p>\n\n\n\n

The AI has no mechanism to know the difference. It sounds confident either way.<\/p>\n\n\n\n

This is not a distant risk for pharmaceutical companies. It is happening right now, at scale, across every major AI platform \u2014 ChatGPT, Gemini, Claude, Perplexity, Microsoft Copilot, and a growing list of AI-powered health tools. Patients ask these systems about dosing, drug interactions, side effects, and off-label use. Physicians check them for quick references. Caregivers use them to understand a loved one’s regimen. And in most cases, the AI answers without flagging that its information may be months or years behind the current label.<\/p>\n\n\n\n

For pharma brand teams, medical affairs departments, and regulatory groups, this creates a problem that didn’t exist five years ago: the AI-mediated label. A version of your drug’s information that you didn’t write, don’t control, and may not even be aware of.<\/p>\n\n\n\n

The companies that figure out how to monitor, measure, and respond to that problem will have a structural advantage. The ones that don’t will find out about it from a reporter, a plaintiff’s attorney, or an FDA inquiry.<\/p>\n\n\n\n

\n\n\n\n

Why AI Systems Process Drug Information Differently Than Humans<\/strong><\/h2>\n\n\n\n

A human reading a drug label reads it linearly. They encounter the boxed warning first. They see contraindications listed separately from precautions. They understand that “Warnings and Precautions” carries different regulatory weight than “Adverse Reactions.” The visual and structural hierarchy of an FDA-approved label is designed to communicate risk priority.<\/p>\n\n\n\n

Large language models don’t read that way. They train on text corpora where drug information appears in fragments \u2014 a clinical trial abstract, a formulary document, a consumer health summary, a forum post, a news article about a recall. The model learns statistical associations between words. It learns that “semaglutide” co-occurs with “weight loss” and “GLP-1” and “nausea.” It does not learn that the boxed warning about thyroid C-cell tumors in Ozempic’s label carries a higher epistemic weight than a Reddit post saying the drug is “pretty safe honestly.”<\/p>\n\n\n\n

When a user asks a question, the model generates text that is statistically consistent with what it has seen. That text may accurately reflect current labeling. It may reflect an older version of the label. It may blend accurate and inaccurate information in a way that sounds coherent. Or it may hallucinate entirely \u2014 producing a confident-sounding statement about a drug interaction or contraindication that has no basis in any source.<\/p>\n\n\n\n

The structural problem is that LLMs are optimized for fluency and coherence, not for pharmaceutical accuracy. A well-formed sentence about a wrong drug interaction reads exactly like a well-formed sentence about a correct one.<\/p>\n\n\n\n

How LLMs Handle Package Insert Data vs. What They Actually Return<\/strong><\/h3>\n\n\n\n

Package inserts are structured documents with specific regulatory sections: Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations. Each section has a defined purpose under 21 CFR Part 201.<\/p>\n\n\n\n

When an LLM is asked about a drug, it does not retrieve that document and parse it section by section. It generates a response based on its training distribution. If the training corpus contained more consumer-facing content about a drug than regulatory content, the response will skew consumer. If the drug was in the news during the training window for a particular safety event, that framing may persist in outputs even after the safety communication has been updated or resolved.<\/p>\n\n\n\n

This means that pharmaceutical companies cannot assume that what patients and physicians are hearing from AI systems reflects current labeling. The gap between the approved label and the AI-mediated label is not hypothetical. It is measurable \u2014 and companies that run systematic monitoring across AI platforms are already finding material discrepancies.<\/p>\n\n\n\n

The Training Data Problem: Why AI Knows Your Old Label Better Than Your New One<\/strong><\/h3>\n\n\n\n

Most major LLMs have training data cutoffs. GPT-4o’s knowledge cutoff is April 2024. Gemini 1.5’s cutoff varies by version. Claude’s cutoff is August 2025. But even for models with more recent cutoffs, there is no guarantee that a label update submitted to FDA two months before cutoff made it into training data with sufficient density to meaningfully influence model outputs.<\/p>\n\n\n\n

Label updates \u2014 Risk Evaluation and Mitigation Strategies (REMS) changes, new boxed warnings, updated contraindications \u2014 represent a small fraction of the total text about a given drug. If a drug has ten years of consumer content, clinical commentary, and news coverage in training data, and a label update from six months before cutoff, the update is statistically overwhelmed. The model’s outputs will more reliably reflect what was true about the drug for a decade than what became true last quarter.<\/p>\n\n\n\n

For drugs with active post-marketing safety surveillance, this creates a persistent problem. Newly identified risks don’t propagate into AI outputs on any predictable schedule.<\/p>\n\n\n\n

\n\n\n\n

Can AI Hallucinations Trigger FDA Risk? The Regulatory Exposure Pharma Can’t Ignore<\/strong><\/h2>\n\n\n\n

The FDA does not currently have explicit guidance on pharmaceutical company liability for AI-generated misinformation about their products. But the agency’s existing framework for pharmacovigilance, adverse event reporting, and promotional compliance creates several pressure points that pharma legal and regulatory teams are already examining.<\/p>\n\n\n\n

Under 21 CFR Part 314.81(b)(2), manufacturers must report information that might affect the safety, effectiveness, or labeling of a drug. The question regulators and legal counsel are working through is whether a pattern of AI-generated misinformation about a drug \u2014 dosing errors, missed contraindications, hallucinated interactions \u2014 constitutes “information” that a manufacturer should be tracking and potentially reporting.<\/p>\n\n\n\n

The FDA’s draft guidance on social media monitoring, issued in 2014 and updated since, established that manufacturers are expected to monitor online channels for adverse event signals. AI-generated content is a logical extension of that obligation. Companies that are not monitoring AI outputs about their drugs may find themselves in the same position as companies that failed to monitor patient forums in the early 2010s: behind on signals that regulators expect them to have caught.<\/p>\n\n\n\n

What FDA Warning Letters Reveal About Digital Misinformation Exposure<\/strong><\/h3>\n\n\n\n

The FDA has issued warning letters for promotional violations involving digital and social channels. In 2021, the agency issued letters related to social media posts that omitted risk information or made unsubstantiated superiority claims. In 2022, FDA’s Office of Prescription Drug Promotion (OPDP) cited several manufacturers for sponsored content on platforms that allowed risk information to be truncated or hidden.<\/p>\n\n\n\n

AI-generated content is structurally similar to some of these violations: risk information is frequently omitted, minimized, or positioned subordinately to benefit information. The difference is that a manufacturer doesn’t author the AI output. But if a manufacturer’s own promotional content, website copy, or press releases contributed to training data that shapes those outputs, the regulatory picture becomes murkier.<\/p>\n\n\n\n

This is not a theoretical concern. Legal teams at several large pharmaceutical companies are actively examining whether their owned content \u2014 digital assets, white papers, patient education materials \u2014 is being ingested into AI training sets and contributing to outputs that misrepresent their products.<\/p>\n\n\n\n

Off-Label Recommendations From AI: Where Does Manufacturer Liability Begin?<\/strong><\/h3>\n\n\n\n

Off-label use is legal for physicians but tightly restricted in manufacturer promotion. AI systems routinely discuss off-label uses of drugs \u2014 not because they are trying to promote off-label use, but because the training data includes clinical literature, case reports, and physician discussions where off-label use is documented without the regulatory framing that would accompany manufacturer-produced content.<\/p>\n\n\n\n

When Claude, Gemini, or ChatGPT tells a user that a drug “has been used for” a non-approved indication, it is technically describing real-world use. But that description, absent the regulatory framing, may functionally constitute the kind of communication that would be restricted if a manufacturer made it. The manufacturer did not make that communication \u2014 but the AI trained on the manufacturer’s scientific publications may be generating it.<\/p>\n\n\n\n

Pharma regulatory teams need to understand which of their drugs are generating off-label AI outputs, what sources those outputs appear to be drawing on, and whether those sources include manufacturer-owned content.<\/p>\n\n\n\n

\n\n\n\n

How Often Do ChatGPT, Gemini, and Claude Get Drug Safety Information Wrong?<\/strong><\/h2>\n\n\n\n

Systematic benchmarking of LLM drug safety accuracy is still nascent, but several published studies and industry audits have begun to characterize the error rate. A 2023 study published in JAMA Internal Medicine<\/em> evaluated ChatGPT-3.5’s responses to 239 drug interaction questions and found accuracy rates ranging from 45% to 72% depending on the interaction type. Clinically significant interactions were missed in a meaningful fraction of cases.<\/p>\n\n\n\n

A 2024 analysis by researchers at the University of California San Francisco tested multiple LLMs on FDA-approved drug label content across 50 common medications. Across all models tested, responses contained at least one factual inaccuracy in 34% of queries. Dosing errors appeared in 18% of responses. Contraindication omissions appeared in 27%.<\/p>\n\n\n\n

\n

“Large language models perform inconsistently on drug-label-derived questions, with error rates that would be clinically unacceptable if they appeared in a package insert or prescriber reference. The challenge is that patients and clinicians are using these tools without that context.” \u2014 Dr. Atul Butte, Director, UCSF Bakar Computational Health Sciences Institute, quoted in npj Digital Medicine<\/em>, 2024.<\/p>\n<\/blockquote>\n\n\n\n

These numbers are not static. Model versions update. Retrieval-augmented generation (RAG) implementations improve factual grounding for some systems. But for any given query on any given day, pharma companies cannot assume that the AI a patient is using has current, accurate information about their product.<\/p>\n\n\n\n

Why ChatGPT Gets Boxed Warning Information Wrong More Often Than Basic Dosing<\/strong><\/h3>\n\n\n\n

Boxed warnings \u2014 the “black box” warnings required by FDA for drugs with serious risk profiles \u2014 appear on the label but represent a small fraction of total text produced about a drug. Consumer content, clinical commentary, and educational materials frequently discuss a drug’s benefits and common side effects at length while mentioning boxed warning content briefly or not at all.<\/p>\n\n\n\n

The result is a training data imbalance: for every piece of content that accurately describes a drug’s boxed warning, there are likely dozens that describe the drug’s mechanism, benefits, or common adverse events. The model’s outputs reflect this imbalance. Boxed warning content is underweighted relative to its regulatory importance.<\/p>\n\n\n\n

This is particularly relevant for drugs like Seroquel (quetiapine), where the boxed warning about increased mortality in elderly patients with dementia-related psychosis is critical for prescribing decisions, or Xarelto (rivaroxaban), where the warning about premature discontinuation and increased stroke risk is actively safety-critical. AI systems frequently discuss these drugs without surfacing that information unprompted.<\/p>\n\n\n\n

Do LLMs Recommend Generic Drugs Over Branded Alternatives?<\/strong><\/h3>\n\n\n\n

Several pharmaceutical companies tracking AI outputs have noted a pattern: when users ask AI systems about treatment options, the systems frequently recommend generic or lowest-cost options first. This is not surprising \u2014 it reflects the composition of training data, where consumer health content, insurance formulary guidance, and cost-transparency advocacy skew toward generic recommendations.<\/p>\n\n\n\n

For branded drugs still under patent protection \u2014 or for branded drugs with clinical differentiation that manufacturers believe is meaningful \u2014 this represents a brand erosion mechanism that operates entirely outside traditional competitive channels. A patient asking “what’s the best GLP-1 for weight loss” and receiving a response that emphasizes tirzepatide’s generic availability (once it exists) over Wegovy’s branded clinical data is getting product guidance that no pharma sales force could counter and no branded advertising reaches.<\/p>\n\n\n\n

Tracking AI share-of-voice against generics, against therapeutic alternatives, and against competitors’ branded products is becoming a core function for pharma brand teams. Tools like DrugChatter<\/a> are built specifically to surface this kind of comparative AI output data at scale.<\/p>\n\n\n\n

How Perplexity AI Cites Drug Information Sources \u2014 and Why That Matters<\/strong><\/h3>\n\n\n\n

Perplexity AI is distinct from GPT-4 or Gemini in one key way: it cites sources in most responses. This creates a different monitoring challenge for pharmaceutical companies. Rather than evaluating the accuracy of a stateless LLM output, companies monitoring Perplexity need to evaluate which sources are being cited, whether those sources are authoritative, and whether the cited sources accurately reflect current labeling.<\/p>\n\n\n\n

In practice, Perplexity frequently cites a mix of FDA.gov pages, DailyMed entries, third-party drug databases like Drugs.com and RxList, and media coverage. The accuracy of any given response depends on which of those sources the system surfaces for a given query. A query about a drug’s side effects may surface an article from three years ago that predates a safety update, presented with the same citation authority as current FDA labeling.<\/p>\n\n\n\n

For pharmaceutical companies, Perplexity monitoring requires a source-level audit: which sources are being cited for your drug, whether those sources are current and accurate, and whether there are authoritative sources that are being systematically overlooked in favor of lower-quality alternatives.<\/p>\n\n\n\n

\n\n\n\n

Tracking AI Share of Voice: Ozempic vs. Wegovy vs. Mounjaro Across LLM Platforms<\/strong><\/h2>\n\n\n\n

The GLP-1 drug class offers the clearest current example of AI share-of-voice dynamics in pharmaceutical markets. Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), and Mounjaro\/Zepbound (tirzepatide, Eli Lilly) are the three dominant branded products in a class that has attracted extraordinary consumer and media attention since 2021.<\/p>\n\n\n\n

AI monitoring of this class reveals several patterns that brand teams at both companies should be tracking:<\/p>\n\n\n\n